Eli Lilly and Company $LLY Shares Purchased by Alhambra Investment Management LLC

Key Points

• Alhambra Investment Management LLC increased its stake in Eli Lilly and Company by 92.9%, holding a total of 924 shares valued at $720,000.
• In the recent quarter, insiders purchased a total of 4,514 shares of Eli Lilly stock, valued at approximately $2.9 million.
• Eli Lilly reported strong quarterly earnings of $6.31 per share, exceeding expectations and reflecting a 37.6% increase in revenue year-over-year.

Alhambra Investment Management LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 92.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 924 shares of the company's stock after acquiring an additional 445 shares during the period. Alhambra Investment Management LLC's holdings in Eli Lilly and Company were worth $720,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. WestEnd Advisors LLC grew its holdings in shares of Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after buying an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the first quarter worth about $27,000. Citizens National Bank Trust Department grew its holdings in shares of Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after buying an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. purchased a new stake in shares of Eli Lilly and Company during the first quarter worth about $40,000. Finally, TD Capital Management LLC grew its holdings in shares of Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company's stock worth $46,000 after buying an additional 31 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Eli Lilly and Company news, Director Jamere Jackson purchased 200 shares of Eli Lilly and Company stock in a transaction on Friday, August 8th. The shares were purchased at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. This represents a 2.17% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director J Erik Fyrwald purchased 1,565 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were acquired at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director owned 74,578 shares of the company's stock, valued at $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 4,514 shares of company stock valued at $2,894,841 over the last quarter. 0.14% of the stock is owned by insiders.

Eli Lilly and Company Trading Down 1.0%

Shares of LLY stock opened at $747.29 on Wednesday. The stock has a market cap of $707.27 billion, a price-to-earnings ratio of 48.84, a price-to-earnings-growth ratio of 1.05 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $939.30. The firm's 50 day moving average price is $736.98 and its two-hundred day moving average price is $768.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company's revenue was up 37.6% compared to the same quarter last year. During the same period in the previous year, the company posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on LLY shares. HSBC upgraded shares of Eli Lilly and Company from a "reduce" rating to a "hold" rating and lifted their price target for the stock from $675.00 to $700.00 in a report on Wednesday, August 27th. Berenberg Bank reiterated a "hold" rating and set a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Leerink Partnrs cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. Morgan Stanley reissued an "overweight" rating and issued a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Finally, Wall Street Zen cut shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Saturday. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and an average price target of $939.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.